Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 50 results for sight loss

  1. Boston Keratoprosthesis Type I for corneal blindness (MIB91)

    NICE has developed a medtech innovation briefing (MIB) on Boston Keratoprosthesis Type I for corneal blindness .

  2. Diabetic retinopathy: management and monitoring (NG242)

    This guideline covers managing and monitoring diabetic retinopathy in people under the care of hospital eye services. This includes non-proliferative and proliferative diabetic retinopathy, and diabetic macular oedema.

  3. Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)

    Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.

  4. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence (CG76)

    This guideline covers medicines adherence in people aged 18 and over. It recommends how to encourage adherence to medicines by supporting and involving people in decisions about their prescribed medicines. It aims to ensure that a person’s decision to use a medicine is an informed choice.

  5. Ranibizumab for treating diabetic macular oedema (TA274)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.

  6. Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)

    NICE has developed a medtech innovation briefing (MIB) on Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema .

  7. AI technologies for detecting diabetic retinopathy (MIB265)

    NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .

  8. Physical health of people in prisons (QS156)

    This quality standard covers assessing, diagnosing and managing physical health problems of adults aged 18 years and older in prisons or young offender institutes. It describes high-quality care in priority areas for improvement.

  9. Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (TA229)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema following retinal vein occlusion in adults.

  10. Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (TA305)

    Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by macular oedema from central retinal vein occlusion in adults.

  11. Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.

  12. Holoclar for treating limbal stem cell deficiency after eye burns (TA467)

    Evidence-based recommendations on Holoclar (a layer of cells grown from cells taken from your own eye) for treating limbal stem cell deficiency in adults with eye burns.

  13. Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis (CG95)

    This guideline covers assessing and diagnosing recent chest pain in people aged 18 and over and managing symptoms while a diagnosis is being made. It aims to improve outcomes by providing advice on tests (ECG, high-sensitivity troponin tests, multislice CT angiography, functional testing) that support healthcare professionals to make a speedy and accurate diagnosis.

  14. Icare rebound tonometer to measure intraocular pressure (MIB57)

    NICE has developed a medtech innovation briefing (MIB) on the Icare rebound tonometer to measure intraocular pressure

  15. The SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional changes in people with or at risk of developing glaucoma (MIB14)

    NICE has developed a Medtech Innovation Briefing (MIB) on the SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional